Cargando…

Proton Pump Inhibitors and Hospitalization with Hypomagnesemia: A Population-Based Case-Control Study

BACKGROUND: Some evidence suggests that proton pump inhibitors (PPIs) are an under-appreciated risk factor for hypomagnesemia. Whether hospitalization with hypomagnesemia is associated with use of PPIs is unknown. METHODS AND FINDINGS: We conducted a population-based case-control study of multiple h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zipursky, Jonathan, Macdonald, Erin M., Hollands, Simon, Gomes, Tara, Mamdani, Muhammad M., Paterson, J. Michael, Lathia, Nina, Juurlink, David N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181956/ https://www.ncbi.nlm.nih.gov/pubmed/25268962 http://dx.doi.org/10.1371/journal.pmed.1001736

Ejemplares similares

Proton pump inhibitors and hypomagnesemia monitoring
por: Lemon, Thomas I
Publicado: (2013)

Symptomatic hypomagnesemia and proton pump inhibitors
por: Tin, Sim Sai, et al.
Publicado: (2014)

Proton Pump Inhibitors and the Risk of Adverse Cardiac Events
por: Juurlink, David N., et al.
Publicado: (2013)

Mechanisms of proton pump inhibitor‐induced hypomagnesemia
por: Gommers, Lisanne M. M., et al.
Publicado: (2022)

Is hypomagnesemia associated with using proton pump inhibitors?
por: Yi, Joo-Hark, et al.
Publicado: (2016)

Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study
por: Fralick, Michael, et al.
Publicado: (2014)

Hypomagnesemia Induced by Long-Term Treatment with Proton-Pump Inhibitors
por: Janett, Simone, et al.
Publicado: (2015)

Proton-pump inhibitor use amongst patients with severe hypomagnesemia
por: Seah, Sherry, et al.
Publicado: (2023)

Proton pump inhibitors and hypomagnesemia: A meta-analysis of observational studies
por: Srinutta, Thawin, et al.
Publicado: (2019)

Proton Pump Inhibitor Prophylaxis After Gastric Bypass Does Not Cause Hypomagnesemia
por: Boerlage, Thomas C. C., et al.
Publicado: (2016)

Prevalence and outcomes of proton pump inhibitor associated hypomagnesemia in chronic kidney disease
por: Hughes, John, et al.
Publicado: (2018)

Proton Pump Inhibitor-Induced Hypomagnesemia: A Rare, Potentially Fatal Complication
por: Pawlukiewicz, Alec J, et al.
Publicado: (2020)

A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors
por: Cressman, Alex M, et al.
Publicado: (2015)

Persistent severe hypomagnesemia caused by proton pump inhibitor resolved after laparoscopic fundoplication
por: Semb, Synne, et al.
Publicado: (2017)

Proton-pump Inhibitor-induced Severe Hypomagnesemia and Hypocalcemia are Clinically Masked by Thiazide Diuretic
por: Uehara, Atsuko, et al.
Publicado: (2019)

Prescription Stimulant Use and Hospitalization for Psychosis or Mania: A Population-Based Study
por: Cressman, Alex M., et al.
Publicado: (2015)

Prescription of oxycodone versus codeine after childbirth and risk of persistent opioid use: a population-based cohort study
por: Zipursky, Jonathan S., et al.
Publicado: (2023)

Maternal opioid treatment after delivery and risk of adverse infant outcomes: population based cohort study
por: Zipursky, Jonathan S, et al.
Publicado: (2023)

The Association between the Use of Proton Pump Inhibitors and the Risk of Hypomagnesemia: A Systematic Review and Meta-Analysis
por: Park, Chan Hyuk, et al.
Publicado: (2014)

Does the use of proton pump inhibitors increase the risk of hypomagnesemia: An updated systematic review and meta-analysis
por: Liao, Shengtao, et al.
Publicado: (2019)

The Association between the Use of Proton Pump Inhibitors and the Risk of Hypomagnesemia in a National Cohort of Veteran Patients with HIV
por: Sutton, S. Scott, et al.
Publicado: (2019)

Relationship between long-term use of proton pump inhibitor (PPI) and hypomagnesemia in patients with gastroesophageal reflux disease
por: Arj, Abbas, et al.
Publicado: (2022)

Hypomagnesemia Caused by Chronic Use of Over-the-Counter Proton Pump Inhibitor as a Possible Cause of Supraventricular Tachycardia
por: Ortega, Francisco J, et al.
Publicado: (2023)

Measuring the Burden of Opioid-related Mortality in Ontario, Canada
por: Gomes, Tara, et al.
Publicado: (2018)

The Burden of Opioid-Related Mortality in the United States
por: Gomes, Tara, et al.
Publicado: (2018)

High-Dose Opioid Prescribing and Opioid-Related Hospitalization: A Population-Based Study
por: Spooner, Luke, et al.
Publicado: (2016)

Reformulation of controlled-release oxycodone and pharmacy dispensing patterns near the US–Canada border
por: Gomes, Tara, et al.
Publicado: (2012)

Proton Pump Inhibitor and Tacrolimus Uses are Associated With Hypomagnesemia in Connective Tissue Disease: a Potential Link With Renal Dysfunction and Recurrent Infection
por: Hanaoka, Hironari, et al.
Publicado: (2021)

Trends in Opioid Toxicity–Related Deaths in the US Before and After the Start of the COVID-19 Pandemic, 2011-2021
por: Gomes, Tara, et al.
Publicado: (2023)

The burden of premature opioid-related mortality
por: Gomes, Tara, et al.
Publicado: (2014)

Tramadol and the risk of seizure: nested case-control study of US patients with employer-sponsored health benefits
por: Morrow, Richard L, et al.
Publicado: (2019)

Prior Authorization and Canadian Public Utilization of Direct-Acting Oral Anticoagulants
por: Gao, Lulu, et al.
Publicado: (2017)

Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide
por: Mamdani, Muhammad, et al.
Publicado: (2019)

Trends in opioid use and dosing among socio-economically disadvantaged patients
por: Gomes, Tara, et al.
Publicado: (2011)

Contributions of prescribed and non-prescribed opioids to opioid related deaths: population based cohort study in Ontario, Canada
por: Gomes, Tara, et al.
Publicado: (2018)

Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case–control study
por: Gomes, Tara, et al.
Publicado: (2017)

Impact of delisting high‐strength opioid formulations from a public drug benefit formulary on opioid utilization in Ontario, Canada
por: Martins, Diana, et al.
Publicado: (2019)

A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride
por: Antoniou, Tony, et al.
Publicado: (2018)

Extended-release nifedipine and the risk of intestinal obstruction: a population-based study
por: Juurlink, David N, et al.
Publicado: (2014)

Clinical indications associated with opioid initiation for pain management in Ontario, Canada: a population-based cohort study
por: Pasricha, Sachin V., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_04i7rlrmr5fgnvqp5rj5l32ltt